CD88 Antibody (W17/1): sc-53796

CD88 Antibody (W17/1) is a mouse monoclonal IgG1 antibody that detects CD88 in human samples through applications such as immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). CD88, also known as the C5a receptor (C5aR), is a G protein-coupled integral membrane protein predominantly expressed on immune cells, including neutrophils, monocytes, macrophages, and mast cells, as well as on various epithelial and endothelial cells. Anti-CD88 antibody (W17/1) plays a crucial role in studying inflammatory responses triggered by C5a binding, which leads to the production of acute phase proteins in the liver. CD88′s significance extends to various pathological conditions, including rheumatoid arthritis, where heightened expression is associated with increased inflammation. Research has shown that human bronchial epithelial cells exhibit enhanced responsiveness to C5a when exposed to environmental irritants such as cigarette smoke, highlighting CD88′s importance in both innate immunity and inflammatory disease pathogenesis. CD88 (W17/1) antibody serves as an essential tool for researchers investigating inflammation mechanisms and C5a′s role in various disease states.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD88 Antibody (W17/1) References:

1. Overexpression of wild-type and catalytically inactive forms of GRK2 and GRK6 fails to alter the agonist-induced phosphorylation of the C5a receptor (CD88): evidence that GRK6 is autophosphorylated in COS-7 cells.  |  Milcent, MD., et al. 1999. Biochem Biophys Res Commun. 259: 224-9. PMID: 10334944
2. Intracerebral complement C5a receptor (CD88) expression is regulated by TNF and lymphotoxin-alpha following closed head injury in mice.  |  Stahel, PF., et al. 2000. J Neuroimmunol. 109: 164-72. PMID: 10996218
3. Altered expression of CD88 and associated impairment of complement 5a-induced neutrophil responses in human immunodeficiency virus type 1-infected patients with and without pulmonary tuberculosis.  |  Meddows-Taylor, S., et al. 2001. J Infect Dis. 183: 662-5. PMID: 11170995
4. Mycobacteria-primed macrophages and dendritic cells induce an up-regulation of complement C5a anaphylatoxin receptor (CD88) in CD3+ murine T cells.  |  Connelly, MA., et al. 2007. J Leukoc Biol. 81: 212-20. PMID: 16997854
5. Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats.  |  Breivik, T., et al. 2011. J Periodontal Res. 46: 643-7. PMID: 21722134
6. Signaling of the Complement Cleavage Product Anaphylatoxin C5a Through C5aR (CD88) Contributes to Pharmacological Hematopoietic Stem Cell Mobilization.  |  Bujko, K., et al. 2017. Stem Cell Rev Rep. 13: 793-800. PMID: 28918528
7. CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human skin.  |  Werfel, T., et al. 1996. J Immunol. 157: 1729-35. PMID: 8759762
8. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system.  |  Gasque, P., et al. 1997. Am J Pathol. 150: 31-41. PMID: 9006319
9. Functional expression and modulation of C5a receptor (CD88) on skin dendritic cells.  |  Morelli, A., et al. 1997. Adv Exp Med Biol. 417: 133-8. PMID: 9286351
10. Receptors for the anaphylatoxin C5a (CD88) on human mesangial cells.  |  Wilmer, WA., et al. 1998. J Immunol. 160: 5646-52. PMID: 9605171

The preferred CD88 antibody is CD88 Antibody (B-6): sc-271949.